We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Shima M, Nagao A, Taki M, et al. Haemophilia. 2021 Jan;27(1):81-89.

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Sampei Z, Igawa T, Soeda T, et al. PLoS One 2013;8:e57479.

Emicizumab for hemophilia A with factor VIII inhibitors

Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Expert Rev Hematol. 2018;11(11):835-846.

Factor VIIIa-mimetic Cofactor Activity of a Bispecific Antibody to Factors IX/IXa and X/Xa, Emicizumab, Depends on Its Ability to Bridge the Antigens.

Kitazawa T, Esaki K, Tachibana T, et al. Thromb Haemost 2017;117:1348–1357.

Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor

Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Int J Hematol. 2021 Jun;113(6):789-796

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. Haemophilia. 2019;25(4):676-684.

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.

Furukawa S, Nogami K, Shimonishi N, et al. Br J Haematol 2020; DOI: 10.1111/bjh.16574 (ePub ahead of print).

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Batsuli G, Greene A, Meeks SL, Sidonio RF. Res Pract Thromb Haemost. 2021 Feb 8;5(2):342-348

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Young G. Blood Adv. 2018;2(20):2780-2782.